This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two ...

It is a high-risk, high-potential reward situation for only the hardiest of investors. Tonix Pharmaceuticals is a ...

The FDA accepts Tonix Pharmaceuticals' New Drug Application (NDA) for TNX-102 SL. The NDA is backed by two successful Phase 3 trials showing significant pain reduction, with TNX-102 SL being ...

Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia ...

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration, FDA, assigned a Prescription Drug User Fee Act, PDUFA, goal date of August 15, 2025, for a decision on marketing ...

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration, FDA, has accepted the filing of its New Drug Application, NDA, for TNX-102 SL, a 5.6 mg, non-opioid, centrally ...

CHATHAM, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and ...

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company announced that the U.S. Food and Drug Administration (FDA) accepted its ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations ...